跳至主要内容
临床试验/NCT05260164
NCT05260164已完成不适用

Effect of BTL-899 Device for Non-invasive Lipolysis on Human Flanks

BTL Industries Ltd.1 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2022年3月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
55
试验地点
1
主要终点
Change of fat thickness in the flanks area evaluated by ultrasound

研究概览

简要总结

This study will evaluate the clinical safety and the performance of the BTL-899 device (with its 899-AP-C-4 and 899-AP-C-5 applicators) during treatment of the flanks (also known as "love handles"). The study has a single-arm, open-label, interventional design. The subjects will be enrolled and assigned into one study arm and will be required to complete four (4) treatment visits.

Both flanks will be treated simultaneously for 30 minutes per session. The flanks' fat thickness reduction will be documented by ultrasound.

At the baseline visits health status will be assessed and, if needed, additional tests will be performed. Inclusion and exclusion criteria will be verified and informed consent will be signed.

The treatment administration phase consists of four (4) treatment visits, delivered 5 - 10 days apart.

At every treatment visit after the first, prior to the procedure, the participants will be assessed for adverse effects resulting from the previous treatment(s) with the BTL-899 device.

Safety measures will include documentation of adverse events (AE) during and after the procedures.

Follow-ups visits at 1 month and 3 months after the final treatment will be held.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Body Mass Index (BMI) of 20 to 35 kg/m
  • Visible excess of adipose tissue confirmed with pinch test at the flanks ("love handles") area.
  • Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring and/or weight loss during study participation.
  • Successful initial determination of the flanks' fat thickness by means of ultrasound.
  • No procedure for fat reduction at the treated area in the last six months.
  • Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting a significant change of weight in either direction during study participation.
  • Age between 18 and 70 years.

排除标准

  • Electronic implants (such as intrauterine device, cardiac pacemakers, defibrillators, and neurostimulators)
  • Metal implants
  • Drug pumps
  • Malignant tumor
  • Pulmonary insufficiency
  • Injured or otherwise impaired muscles in the treatment area
  • Cardiovascular diseases
  • Disturbance of temperature or pain perception
  • Hemorrhagic conditions
  • Septic conditions and empyema
  • Acute inflammations
  • Systemic or local infection such as osteomyelitis and tuberculosis
  • Contagious skin disease
  • Elevated body temperature
  • Pregnancy, postpartum period, nursing
  • Graves' disease
  • Scars, open lesions, and wounds at the treatment area
  • Abdominal hernia
  • Gynecological disease incl. inflammation in the pelvis
  • Hip and rib cage trauma or recent surgery of those
  • Previous liposuction in the treatment area in the last six months
  • Unstable weight within the last 6 months (change in weight ± 3%)
  • Previous body contouring or cellulite treatments in the flanks area in the last six months
  • Any other disease or condition at the investigator's discretion

结局指标

主要结局

Change of fat thickness in the flanks area evaluated by ultrasound

时间窗: 5 months

To gather clinical evidence that the BTL-899 device is able to induce non-invasive lipolysis when used on human flanks

次要结局

  • Evaluation of the Therapy's Safety Measured Via Therapy Comfort Questionnaire(5 months)
  • Evaluation of the participants' satisfaction with the therapy evaluated via standard questionnaires(5 months)

研究者

发起方
BTL Industries Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验